Abstract |
DL-threo-3,4-dihydroxyphenylserine (DL- threo-DOPS) was administered during 10 days to 4 patients with longstanding Parkinson's disease in addition to their treatment with L-3,4-dihydroxyphenyl-L-alanine ( L-DOPA)- carbidopa ( Sinemet). All patients tended to improve in their symptoms freezing, all day life activity and mood. There were no improvements in rigidity, tremor, and akinesia (in general). During the DL- threo-DOPS-treatment cerebrospinal fluid (CSF), serum and urine concentrations of catecholamines were measured. The results show that DL- threo-DOPS is transported to the brain and CSF in a way comparable with L-DOPA. However, no measurable increase of 3-methoxy-4-hydroxyphenylethyleneglycol ( MOPEG) in CSF could be demonstrated. This suggests that the synthesis of noradrenaline from DL- threo-DOPS in the brain is doubtful. In addition measurements in urine reveals that at the dose used Sinemet prevents peripheral decarboxylation of DL- threo-DOPS into noradrenaline. Other possible metabolic pathways of DL- threo-DOPS are discussed.
|
Authors | A W Teelken, G A van den Berg, F A Muskiet, A L Staal-Schreinemachers, B G Wolthers, J P Lakke |
Journal | Journal of neural transmission. Parkinson's disease and dementia section
(J Neural Transm Park Dis Dement Sect)
Vol. 1
Issue 3
Pg. 177-88
( 1989)
ISSN: 0936-3076 [Print] Austria |
PMID | 2476157
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Catecholamines
- 3,4-Dihydroxyphenylacetic Acid
- Serine
- Hydroxyindoleacetic Acid
- Droxidopa
- Dopamine
- Homovanillic Acid
|
Topics |
- 3,4-Dihydroxyphenylacetic Acid
(metabolism)
- Aged
- Catecholamines
(metabolism)
- Dopamine
(metabolism)
- Droxidopa
(therapeutic use)
- Female
- Homovanillic Acid
(metabolism)
- Humans
- Hydroxyindoleacetic Acid
(metabolism)
- Male
- Middle Aged
- Parkinson Disease, Secondary
(drug therapy, metabolism)
- Serine
(analogs & derivatives)
|